KRAS and colorectal carcinoma: Furthermore, in a cohort of KRAS wild type metastatic CRC patients treated with anti-EGFR treatment, those with higher expression and activation of EGFR and HER3 membrane receptors had a better OS, independently of the line of treatment [67].